Laura"Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enbable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect."
Wow. 😮
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
#tuberculosis #PatientsNotPatents
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB